Equities
Health CarePharmaceuticals & Biotechnology
  • Price (DKK)182.70
  • Today's Change-5.80 / -3.08%
  • Shares traded450.99k
  • 1 Year change-28.44%
  • Beta1.3660
Data delayed at least 15 minutes, as of Dec 03 2020 15:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

  • Revenue in DKK (TTM)17.82bn
  • Net income in DKK1.44bn
  • Incorporated1950
  • Employees5.76k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hansa Biopharma AB2.52m-309.03m7.96bn80.00--8.20--3,157.83-10.36-10.360.084630.090.0031--0.599546,932.43-37.66-38.19-40.76-41.5571.6785.18-12,262.51-4,954.36----0.0051--0.178715.76-45.18--23.28--
Camurus AB192.62m-126.01m7.98bn134.00--13.35--41.42-3.36-3.365.1015.360.34140.55988.022,212,092.00-22.33-34.29-27.07-42.7586.3192.92-65.42-200.023.66-158.480.028--114.12-12.70-23.52--29.19--
Oncopeptides AB0.00-962.64m8.11bn232.00--10.41-----22.20-22.200.0015.810.00----0.00-107.60-109.07-125.68-137.31-----------1,200.320.00-------80.17------
Zealand Pharma A/S301.45m-659.86m9.29bn329.00--5.83--30.81-17.49-17.498.0240.040.1598--13.621,684,084.00-34.98-12.24-41.57-13.7575.52---218.89-84.515.55-23.650.0775--8.84-23.11-198.32--39.22--
Recipharm AB (publ)7.43bn148.75m9.92bn7.38k67.562.2711.071.342.542.54123.4475.490.56763.086.451,490,204.001.141.521.281.7547.4148.072.002.771.592.760.580234.2317.0023.75115.1816.4511.35--
Karo Pharma AB2.04bn62.50m10.34bn129.00163.572.5025.935.070.3870.38712.4125.290.2403----21,773,020.000.7443.691.154.9354.9253.203.1015.21--1.680.17416.4617.71129.20-98.65--12.32--
AddLife AB3.29bn252.23m10.34bn988.0041.938.3024.503.153.093.0940.1915.631.325.826.674,860,944.0010.23--17.61--34.22--7.73--0.602427.640.3089--40.21--8.74------
Bavarian Nordic A/S1.91bn606.31m10.77bn649.0013.002.0412.125.6314.1714.1741.4690.120.31864.6020.945,906,361.0010.09-2.8212.11-3.6147.6066.7931.68-9.591.5445.190.4102--32.33-11.454.19--27.95--
Vaccibody AS60.75k-113.19m12.20bn36.00--115.48--200,821.40-2.29-2.290.00080.53340.0004--0.00843,625.00-67.04-27.40-72.25-29.59-----186,331.00-16,364.47----0.00--279.57---50.42------
ALK-Abello A/S3.38bn27.00m21.74bn2.41k928.747.3174.186.422.312.31310.05293.410.63541.297.211,414,889.000.50711.010.60511.2158.0560.640.79811.611.203.100.230243.2212.326.1270.59---3.73--
Swedish Orphan Biovitrum AB (publ)11.30bn2.25bn36.04bn1.47k15.642.579.743.1910.4510.4552.4063.700.40481.647.5611,662,920.008.0710.699.4413.6378.0372.9219.9420.190.41699.020.41480.0055.9140.4536.65--121.42--
H. Lundbeck A/S17.82bn1.44bn37.44bn5.76k26.042.5510.002.107.227.2289.6473.850.61381.974.733,068,894.004.944.106.726.1578.3076.008.055.710.945236.120.4033112.00-5.974.81-31.74---22.11--
Orion Oyj8.17bn1.78bn40.79bn3.42k22.687.1518.454.991.711.717.835.421.081.756.71336,049.0023.5720.1428.1725.7461.3260.2021.8320.852.47177.000.124795.627.520.69361.52-1.05-8.492.90
Data as of Dec 03 2020. Currency figures normalised to H Lundbeck A/S's reporting currency: Danish Krone DKK

Institutional shareholders

6.88%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 20192.49m1.25%
Invesco Advisers, Inc.as of 30 Jun 20202.00m1.00%
The Vanguard Group, Inc.as of 31 Oct 20201.80m0.90%
Polar Capital LLPas of 30 Sep 20201.39m0.70%
BlackRock Fund Advisorsas of 05 Nov 20201.38m0.69%
Handelsbanken Fonder ABas of 31 Oct 20201.31m0.66%
Nordea Investment Management AB (Denmark)as of 31 Aug 20201.10m0.56%
Dimensional Fund Advisors LPas of 30 Sep 2020852.11k0.43%
BlackRock Advisors (UK) Ltd.as of 05 Nov 2020743.07k0.37%
UBS Asset Management (Americas) Inc.as of 26 Nov 2020615.00k0.31%
More ▼
Data from 31 Dec 2019 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.